Design and Implementation of a Design and Implementation of a The Integration of Additive Manufacturing into Traditional Manufacturing Processes

Author: Jazmin E. López González
Master in Manufacturing Competitiveness
Advisor: Rafael A. Nieves-Castro, PharmD.
Graduate Project EXPO, October 2025

Abstract

Abstract *— The pharmaceutical industry is undergoing a rapid transformation driven by technological advances, economic pressures, and changing consumer demands. Integrating additive manufacturing (AM) into traditional processes offers opportunities for personalized medicine, waste reduction, and enhanced production efficiency, while maintaining regulatory compliance. This study proposes a framework based on the DMADV methodology to design and validate a hybrid manufacturing model supporting personalized drug production. Preliminary results suggest that a structured approach can overcome technical and regulatory barriers, facilitating the adoption of AM in the pharmaceutical sector. The developed framework provides a practical pathway for companies to implement innovative manufacturing strategies, improving responsiveness to market needs and advancing industry competitiveness in a dynamic environment.*
Key Terms — DMADV method, Additive manufacturing, personalization, hybrid process, pharmaceutical industry.

Problem Statement

This research focuses on the integration of additive manufacturing into traditional manufacturing processes within the pharmaceutical industry, aiming to drive innovation, improve efficiency, and promote medication personalization. The need to adopt hybrid approaches arises from the limitations of conventional techniques in producing complex formulations tailored to patients' specific needs, especially in a context where the demand for personalized medicine and the reduction of costs and waste are increasingly important. The integration of these technologies offers potential benefits, such as the ability to create controlled-release systems and customized doses, but also faces technical, regulatory, and economic barriers that hinder widespread adoption. The study seeks to understand how to harmonize these processes by developing a structured framework that facilitates the effective implementation of hybrid manufacturing technologies, enabling pharmaceutical companies to optimize production, comply with regulations, and meet market demands. This research will contribute to identifying strategies and solutions to overcome existing barriers, fostering a transition toward more flexible, sustainable, and innovative processes. The presentation of preliminary results and the associated table will occur during the initial phase of the project, which covers the period from August 1, 2025, to September 4, 2025.

Methodology

We use the DMADV methodology to design and implement the Integration of Additive Manufacturing in to Traditional Manufacturing Processes. This methodology should be implemented in Six Sigma's projects when a new process, product, or service will be designed or redesigned, and it must meet specific requirements. In Table 1, we can learn a brief definition of the five phases of the DMADV methodology. Figure 1 shows the project timeline propose for this project.

Table 1: DMAVD Methodology		Timeline
DEFINE	Define the process and establish goal	August 1 – August 7
MEASURE	Measure to determine process needs	August 8 – Sep 11
ANALYZE	Analyze the data to find the best design	September 12 – September 18
DESIGN	Design and test the process	September 19 – September 25
VERIFY	Ensure that design meets the design input requirements to achieve the goal	Sep-25



Figure 1: Project Timeline in August 2025

Results and Discussion

DEFINE PHASE

Table: 2 Project Charter	
Project Description	Design and implement a integration of Additive Manufacturing into traditional manufacturing processes using DMAVD methodology.
Project timeline	From August 2025 to September 2025.
Project Goal	To design and validate a framework that integrates additive manufacturing into conventional pharmaceutical processes.
Benefits	Sales Team - Offers personalized solutions to clients, enhancing sales opportunities. Financial - Reduces costs associated with material waste Career Development - Develops skills in advanced manufacturing technologies
Project Support	Project Coordinator
Project Member	Project Member | Researcher, Additive Manufacturing Team

MEASURE PHASE



Figure 2: Graphic Benefits of Hybrid Manufacturing



Figure 3: Perception of feasibility and regulatory challenges

ANALYZE PHASE



Figure 4: Perceived benefits of Integration

Results and Discussion

Obstacle	Percentage (%)	Comments
High initial costs	82%	Investment seen as significant
Limited availability of certified materials	65%	Material limitations for pharma-grade AM
Regulatory uncertainty	70%	Need for clear legal frameworks

Figure 5: Main barriers reported

DESIGN PHASE



Figure 6: Proposed Framework for Hybrid Manufacturing

This figure illustrates the systematic process for integrating AM into pharmaceutical production, emphasizing the key steps and phases.



Figure 7: Graphic Perception of Feasibility and Regulatory Concerns

This figure graphically represents industry perceptions regarding the feasibility of AM and the regulatory concerns that influence adoption decisions.

VERIFY PHASE



Figure 8: Graphic Main Benefits

Results and Discussion



Figure 9: Graphic Main Obstacles

This figure depicts the primary barriers to implementation, including costs, material limitations, and regulatory issues.

Conclusions

This chapter encapsulates the main findings, contributions, and implications of the research focused on integrating additive manufacturing (AM) into traditional pharmaceutical processes. The study highlights the considerable opportunities that AM offers for enhancing customization and improving drug formulations, enabling the production of complex delivery systems tailored to individual needs. Despite these promising benefits, significant barriers remain, particularly high initial costs and stringent regulatory frameworks, which hinder the widespread adoption of this technology. The analysis of case studies demonstrates that hybrid manufacturing approaches can effectively increase operational efficiency and reduce lead times, especially in small-batch production scenarios. The research contributes valuable insights through an extensive review of current AM and traditional manufacturing technologies, and by proposing a practical framework designed to address technical, economic, and regulatory challenges, facilitating smoother integration.

Industry perspectives gathered via surveys and interviews provide realistic insights into the practical aspects of implementing hybrid methods, emphasizing the importance of collaboration with regulatory bodies to establish clear guidelines. The findings have profound implications for the future of pharmaceutical manufacturing, including the promotion of personalized medicine, the enhancement of operational flexibility, and cost reduction through combined manufacturing strategies. Nonetheless, the study acknowledges limitations such as reliance on qualitative data, the scope restrictions regarding international regulatory analysis, and the absence of detailed economic evaluations. Future research should focus on expanding regulatory frameworks globally, developing comprehensive economic models, and exploring advanced applications like biologics and vaccines. Overall, the integration of AM signifies a paradigm shift in drug manufacturing, with the potential to transform industry practices and significantly improve patient outcomes. The benefits demonstrated so far underscore its transformative potential and set a solid foundation for ongoing advancements in the field.

Acknowledgements

I would like to sincerely thank Dr. Rafael Nieves, my supervisor and mentor, for his expert guidance and continuous support throughout the completion of this project and during my coursework. His constructive feedback has been instrumental in the successful culmination of this work.

Additionally, I want to especially thank Daimarik Torres for her invaluable advice, support, and trust throughout my master's journey. Her guidance and encouragement have been essential at every stage of this academic path.

Finally, I am grateful to all the professors whose dedication and knowledge have contributed significantly to my academic and personal growth.

References

[1] M. A. Alhnan, T. C. Okwuosa, M. Sadia, K. W. Wan, and W. Ahmed, "Additive manufacturing in drug delivery: Innovative drug product design and opportunities for industrial application," Advanced Drug Delivery Reviews, vol. 108, pp. 39–50, 2016. https://doi.org/10.1016/j.addr.2016.04.018

[2] M. Fera, F. Fruggiero, A. Lambiase, R. Macchiaroli, and S. Miranda, "Integrated traditional and additive manufacturing production profitability model," Computers & Industrial Engineering, vol. 113, pp. 144–157, 2017. https://doi.org/10.1016/j.cie.2017.09.041

[3] A. Goyanes, U. Det-Amornrat, J. Wang, A. W. Basit, and S. Gaisford, "Additive manufacturing and 3D printing of pharmaceutical tablets," International Journal of Pharmaceutics, vol. 499, no. 1-2, pp. 376–381, 2016. https://doi.org/10.1016/j.ijpharm.2015.12.056

[4] Zhang, J., & Choi, S. (2021). Regulatory frameworks and standards for 3D printed medicines. Regulatory Toxicology and Pharmacology, 124, 104954. https://doi.org/10.1016/j.yrtph.2021.104954

[5] Huang, S. H., Liu, P., & Zhang, X. (2020). Additive manufacturing for pharmaceuticals: Opportunities and challenges. International Journal of Pharmaceutics, 586, 119583. https://doi.org/10.1016/j.ijpharm.2020.119583